Emerging NASDAQ company may revolutionize the future of immunotherapy

[This tiny biotech firm aims to bring to market a unique drug candidate that could significantly help millions of people!]( One underfollowed NASDAQ company is developing transformational formulation technologies, enabling a switch from traditional routes to alternative routes of immunotherapy to facilitate local sites of action. This includes nasal, oral, and inhalation administrations to target neurodegenerative diseases. Why is this important? The company believes that if it succeeds in these alternative routes of immunotherapies, it has the potential to revolutionize the way immunotherapies are administered! There are several reasons to have this tiny biotech firm on your radar. The company’s lead asset is Intranasal Foralumab, which has multiple administration routes of a proven systemic anti-inflammatory and is patent protected until 2040. The company’s lead program is in non-active Secondary Progressive Multiple Sclerosis and it is IND cleared and “may proceed” to study foralumab in Alzheimer’s Disease! Foralumab is gaining recognition across the scientific community with features in medical media that include Pharmacy Times. It was also recently highlighted positively in a Forbes article. The company has also submitted an FDA request to obtain an Orphan Drug Designation for intranasal foralumab for the treatment of non-active secondary progressive Multiple Sclerosis (na-SPMS). This request would make foralumab the first therapy for na-SPMS to receive Orphan Drug Designation! [Learn how an experienced scientific advisory board and management team that has brought multiple drugs to market could turn TLSA into a pioneer in immunotherapy treatment.]( --------------------------------------------------------------- MarketMovingTrends c/o CLM Media LLC 45 South Park Place, #203 Morristown New Jersey 07936 USA [Unsubscribe]( | [Change Subscriber Options](